FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMesoblast Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MSB.AX
Mesoblast Limited Stock AnalysisComprehensive stock analysis for Mesoblast Limited (MSB.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMSB.AX
MSB.AX
Mesoblast Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MSB.AX
  1. Home
  2. Stocks
  3. Mesoblast Limited

Mesoblast Limited

🇦🇺MSB.AX•ASX

Mesoblast Limited

🇦🇺MSB.AX•ASX

Your view on MSB.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Mesoblast Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Silviu Itescu
Headquarters
55 Collins Street, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Silviu Itescu
Headquarters
55 Collins Street, Melbourne, VIC, AU
Description

Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland.

Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells.

A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease.

Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease.

The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction.

Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China.

It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Mesoblast Limited. Starting points for Mesoblast Limited: EPS -AUD 0.04, beta 0.81 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Mesoblast Limited. Mesoblast Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Mesoblast Limited. Trailing twelve-month EPS for Mesoblast Limited stands at -AUD 0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026

Hold

Analyst ratings

9 ratings
  • Strong Buy0
  • Buy3
  • Hold4
  • Sell2
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterSep 2026Next quarterDec 2026This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−$0.01−$0.02−$0.02$0.02
Lowest estimate−$0.01−$0.02−$0.03−$0.06
Highest estimate−$0.01−$0.02−$0.01$0.16
Number of analysts1133
A year ago——−$0.051—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterSep 2026Next quarterDec 2026This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate$26.60M$16.37M$197.55M$356.40M
Lowest estimate$26.60M$16.37M$175.10M$266.32M
Highest estimate$26.60M$16.37M$221.78M$429.55M
Number of analysts1166
A year ago——$122.89M—
Growth vs a year ago——+60.8%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Mesoblast Limited. Mesoblast Limited has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MSB.AX14 companies · 8 funds
Compare MSB.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
CMB.AXCambium Bio LimitedHealthcareBiotechnology—
CYP.AXCynata Therapeutics LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PHGUFPharming Group N.V.HealthcareOTC$1.1B
PHIOPhio Pharmaceuticals Corp.HealthcareNASDAQ$7.8M
PHMMFPharma Mar, S.A.HealthcareOTC$1.5B
PHRM.CNPharmaTher Holdings Ltd.HealthcareCNQ$9.1M
PHRRFPharmaTher Holdings Ltd.HealthcareOTC$5.3M
PHVSPharvaris N.V.HealthcareNASDAQ$2.2B
PHYOFIXICO plcHealthcareOTC$6.5M
PKTXProtoKinetix, IncorporatedHealthcareOTC$2.7M
PLRXPliant Therapeutics, Inc.HealthcareNASDAQ$36.9M
PLRZPolyrizon Ltd.HealthcareNASDAQ$10.4M
PLURPluri Inc.HealthcareNASDAQ$10.1M
PLXProtalix BioTherapeutics, Inc.HealthcareAMEX$244.5M
ETFs holding Mesoblast Limited
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.00%
VEAVanguard FTSE Developed Markets ETF$231.6B in assets0.00%
IEFAiShares Core MSCI EAFE ETF$188.8B in assets0.00%
VSSVanguard FTSE All-World ex-US Small-Cap ETF$11.6B in assets0.03%
DFISDimensional - International Small Cap ETF$5.8B in assets0.03%
IPACiShares Core MSCI Pacific ETF$2.6B in assets0.01%
VPLVanguard FTSE Pacific ETF$9.0B in assets0.01%
DFICDimensional - International Core Equity 2 ETF$15.4B in assets0.01%

Largest holders first, then the funds most concentrated in MSB.AX.

Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Mesoblast Limited. Coverage tracks Mesoblast Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Mesoblast Limited.

MSB.AX AnalysisFair
Past
1
Growth
5
Health
4
Profit
1
Value
1